Loading
A phase 1/2 trial of Cetuximab, ADG126, Bevacizumab, Nivolumab and Ipilimumab in advanced solid tumours, run by Sanofi, now recruiting.
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05584670 by Sanofi, with 542 participants planned, started 2022-11-29 and due to reach its primary completion in 2027-01-19. Interventions recorded: SAR445877, Cetuximab, ADG126, Bevacizumab, Nivolumab and Ipilimumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares ADG126, Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bevacizumab, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ipilimumab, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ipilimumab, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Cetuximab, Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ipilimumab, Bevacizumab, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/